Loading
A phase 2 trial of sintilimab and regorafenib in colorectal cancer, run by Fudan University, now recruiting.
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis is a phase 2, interventional study registered as NCT05057052 by Fudan University, with a registry enrolment figure of 25 participants, started 2021-09-26 and due to reach its primary completion in 2026-09-25. Interventions recorded: Sintilimab; Regorafenib; US/CT-guided Percutaneous Cryoablation. Conditions listed: Liver Metastases; Colorectal Cancer Metastatic. Primary outcome: Objective Response Rate (ORR). Colorectal eligibility wording from the registry: "* Participants must have colorectal cancer liver metastasis". Sites: China. No results are recorded here; the registry entry is the source.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Sintilimab, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.